The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects

British Journal of Clinical Pharmacology

Volumn 51, Issue 2, 2001, Pages 147-152

  Ziviani, Luigi ^a   Da Ros, Lucio ^a   Squassante, Lisa ^a   Milleri, Stefano ^a   Cugola, Mauro ^a   Iavarone, Laura E ^a  

^a GSK   (Italy)

Author keywords

HMGCoA reductase inhibitors; Interaction; Lacidipine; Simvastatin

Indexed keywords

CHOLESTEROL; CYTOCHROME P450 3A4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; LACIDIPINE; SIMVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; MALE; MAXIMUM ALLOWABLE CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; ANTILIPEMIC AGENTS; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DIHYDROPYRIDINES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; SIMVASTATIN;

EID: 0035099757     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.051002147.x     Document Type: Article

References (34)

1. National Education Program Working Group report the management of patients with hypertension and high blood cholesterol
2. The effects of antihypertensive agents on serum lipids and lipoproteins
3. French large-scale study evaluating the tolerability and efficacy of lacidipine
4. The impact of lacidipine, a novel dihydropyridine calcium antagonist, on carbohydrate and lipid metabolism
5. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
6. Rhabdomyolysis and renal injury with lovastatin use
7. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine
8. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzime A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin
9. Update: Clinically significant cytochrome P-450 drug interactions
10. Grapefruit juice greatly increases serum concentration of lovastatin and lovastatin acid
11. Grapefruit juice-simvastatin interaction: Effects on serum concentration of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
12. Rhabdomyolysis due to interaction of simvastatin with mibefradil
13. The interaction of diltiazem with lovastatin and pravastatin
14. Selective inhibition of warfarin metabolism by diltiazem in humans
15. Human P450 metabolism of warfarin
16. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 3A4
17. Lacidipine at steady-state does not affect the pharmacokinetics and pharmacodinamics of warfarin
18. Determination of the HMG-CoA reductase inhibitors simvaststin, lovastatin and pravastatin in plasma by gas chromatographic/chemical ionization mass spectrometry
19. Automation and validation of the high-performance liquid chromatographicradioimmunoassay method for the determination of lacidipine in plasma
20. The pharmacokinetics of lacidipine
21. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the mayor enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes
22. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s
23. Roche withdraws Posicor
24. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
25. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
26. In vivo inhibition profile of cytochrome P450 (CYP2C9) by (±)-fluvastatin
27. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
28. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
29. Potential risk of myopathy by HMGCoA reductase inhibitors: A comparison of pravastatin and simvastatin effects on membrane electrical proprieties of rat skeletal muscle fibers
30. Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis
31. Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by prooxidant signals on endotelial cells
32. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day
33. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients